Perceptive Advisors LLC Raises Holdings in Oxford Immunotec Global PLC (OXFD)

Perceptive Advisors LLC grew its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 955.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 465,356 shares of the company’s stock after purchasing an additional 421,250 shares during the period. Perceptive Advisors LLC owned about 1.81% of Oxford Immunotec Global worth $7,818,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Alyeska Investment Group L.P. increased its position in Oxford Immunotec Global by 44.0% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock worth $22,773,000 after purchasing an additional 413,904 shares during the last quarter. RTW Investments LP increased its position in Oxford Immunotec Global by 21.9% in the 3rd quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock worth $17,344,000 after purchasing an additional 185,453 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in Oxford Immunotec Global in the 3rd quarter worth about $2,726,000. Wells Fargo & Company MN increased its position in Oxford Immunotec Global by 31.3% in the 3rd quarter. Wells Fargo & Company MN now owns 38,720 shares of the company’s stock worth $651,000 after purchasing an additional 9,235 shares during the last quarter. Finally, Wasatch Advisors Inc. increased its position in Oxford Immunotec Global by 35.5% in the 3rd quarter. Wasatch Advisors Inc. now owns 574,174 shares of the company’s stock worth $9,646,000 after purchasing an additional 150,343 shares during the last quarter. 89.35% of the stock is currently owned by institutional investors.

Several research analysts have weighed in on the company. Cowen dropped their target price on Oxford Immunotec Global from $22.00 to $19.00 and set an “outperform” rating on the stock in a research report on Thursday, August 17th. Piper Jaffray Companies dropped their target price on Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 31st. Zacks Investment Research lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Saturday, November 4th. BidaskClub lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, BTIG Research began coverage on Oxford Immunotec Global in a research note on Thursday, September 28th. They set a “buy” rating and a $21.00 price target for the company. Three research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Oxford Immunotec Global currently has an average rating of “Hold” and a consensus target price of $19.75.

In other news, CEO Peter Wrighton-Smith sold 55,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $16.78, for a total transaction of $922,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total value of $40,050.00. Following the sale, the director now owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The disclosure for this sale can be found here. Corporate insiders own 8.11% of the company’s stock.

Shares of Oxford Immunotec Global PLC (OXFD) opened at $13.63 on Monday. Oxford Immunotec Global PLC has a 52 week low of $12.19 and a 52 week high of $19.51. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/11/perceptive-advisors-llc-raises-holdings-in-oxford-immunotec-global-plc-oxfd.html.

Oxford Immunotec Global Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

What are top analysts saying about Oxford Immunotec Global PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oxford Immunotec Global PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit